Next Science Ltd (Next Science) is a medical technology company that develops and commercializes non-toxic technology products for antimicrobial resistance and bacterial biofilms. Its products include SurgX, an innovative surgical gel designed to reduce superficial surgical site infections (SSIs) and protect wound tissue that facilitates natural healing; and BlastX, an antimicrobial wound gel that destroys bacteria. Next Science's proprietary Xbio technology is non-toxic and eradicates biofilm-based and free-floating bacteria and reduces the impact of biofilm-based infections in human health. The company has patented applications across multiple market segments, including over-the-counter medications, prescription pharmaceuticals, medical devices and hospital infection control. It operates through its subsidiaries in Australia and the US. Next Science is headquartered in Chatswood, New South Wales, Australia.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Next Science Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Next Science Ltd Company Overview
- Next Science Ltd Company Snapshot
- Next Science Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Next Science Ltd - Pipeline Analysis Overview
- Next Science Ltd - Key Facts
- Next Science Ltd - Major Products and Services
- Next Science Ltd Pipeline Products by Development Stage
- Next Science Ltd Ongoing Clinical Trials by Trial Status
- Next Science Ltd Pipeline Products Overview
- Integrated BlastX Collagen Wound Gel
- Integrated BlastX Collagen Wound Gel Product Overview
- White Label Version - Xperience
- White Label Version - Xperience Product Overview
- XPerience Surgical Rinse
- XPerience Surgical Rinse Product Overview
- XPerience Surgical Rinse Clinical Trial
- Next Science Ltd - Key Competitors
- Next Science Ltd - Key Employees
- Next Science Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Next Science Ltd, Recent Developments
- Apr 18, 2024: Publication of Study Showing Infection Prevention Benefit From XPERIENCE When Used in Primary Joint Arthroplasty Procedures
- Apr 17, 2024: Next Science : 1,400+ Patient Studies Show Zero Percent Infection Rate when using Xperience
- Apr 09, 2024: Publication of Study Showing BLASTX Increases The Efficacy of Negative Pressure Wound Therapy
- Dec 22, 2023: Next Science : Publication of Knee Study Showing Potential Anti-inflammatory Benefit for XPERIENCE
- Nov 03, 2023: Study Finds Infection Prevention Benefit in Periprosthetic Joint Surgery for Xperience Advanced Surgical Irrigation
- Jun 29, 2023: Next Science : Market Update
- Oct 19, 2022: US Medicare accreditation signals growth in Wound Care revenue
- Aug 26, 2022: XPERIENCE cleared for sale in Canada
- May 19, 2022: Oraderm Pharmaceuticals appointed as BlastX distributor for Australia and New Zealand
- May 10, 2022: New study finds XPERIENCE no rinse solution has persistent efficacy against both planktonic bacteria and bacterial biofilms
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Next Science Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Next Science Ltd Pipeline Products by Equipment Type
- Next Science Ltd Pipeline Products by Indication
- Next Science Ltd Ongoing Clinical Trials by Trial Status
- Next Science Ltd, Key Facts
- Next Science Ltd, Major Products and Services
- Next Science Ltd Number of Pipeline Products by Development Stage
- Next Science Ltd Pipeline Products Summary by Development Stage
- Next Science Ltd Ongoing Clinical Trials by Trial Status
- Next Science Ltd Ongoing Clinical Trials Summary
- Integrated BlastX Collagen Wound Gel - Product Status
- Integrated BlastX Collagen Wound Gel - Product Description
- White Label Version - Xperience - Product Status
- White Label Version - Xperience - Product Description
- XPerience Surgical Rinse - Product Status
- XPerience Surgical Rinse - Product Description
- XPerience Surgical Rinse - Clinical Evaluation of the Rate of Total Joint Infection 90-day after Surgery Following Irrigation with Next Science No-Rinse Solution vs SOC Alone
- Next Science Ltd, Key Employees
- Next Science Ltd, Subsidiaries
- Glossary
- Next Science Ltd Pipeline Products by Equipment Type
- Next Science Ltd Pipeline Products by Development Stage
- Next Science Ltd Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Paul Hartmann Pty Ltd
- IRRIMAX Corp
- Stryker Australia Pty Ltd
- SANUWAVE Health Inc
- Sanara MedTech Inc
- Molnlycke Health Care US LLC
